"The Conference was held in Rome at the Ripetta Residence on Friday 5 May"Scientific information of the drug new scenarios".
In the first part of the Conference, focused on State of the art of scientific drug information, the following intervened:
Luigi Patregnani and Loredano Giorni, Heads respectively of the Pharmaceutical Service of the Marche Region and of the Tuscany Region, who illustrated the content of the "Regional Regulation Guidelines" approved on 20 April 2006 by the Regions Conference, Emilio Stefanelli, Vice President of Farmindustria, and Giovanna Scroccaro, President of SIFO, who illustrated the point of view of the Pharmaceutical Industry and SIFO on the indicated topic.
The second part of the conference dealt with the theme "Proposals to improve the quality of Scientific Information on Medicines”, which was developed by Giampaolo Velo (University and Hospital of Verona. Smith-Kline Foundation working group), Salvatore Mannino (Head of Epidemiological Service - ASL Cremona) and Giuseppe Recchia (Vice President Medical and Regulatory - GSK).
In the third part of the Conference, a Panel discussion, which was attended by Claudio Cricelli (SIMG President), Angelo de Rita (AIISF President), Loredano Giorni (Head of Pharmaceutical Services of the Tuscany Region), Onofrio Palombella (Gov. & Reg. Affairs Director AstraZeneca) and Giovanna Scroccaro, President of SIFO. Moderator Claudio Jommi (Editor-in-Chief "Economics & Drug Policy" - Resp. Observ. Medicines CERGAS-SDA Univ. Bocconi). Participants answered the following questions:
1. What are the positive and negative aspects of the current regulation on medical-scientific information according to the different points of view of the players in the health system?
2. Without prejudice to the provisions of Law 326/03 regarding regional competences on medical-scientific information and the Guidelines of the Regional Regulations, is coordination of the regional initiatives between themselves and with AIFA and the pharmaceutical industry associations (through the State-Regions Conference) foreseeable, according to the provisions of article 119 of the Legislative Decree Scheme for the transposition of European directives?
In the first part of the Conference, focused on State of the art of scientific drug information, the following intervened:
Luigi Patregnani and Loredano Giorni, Heads respectively of the Pharmaceutical Service of the Marche Region and of the Tuscany Region, who illustrated the content of the "Regional Regulation Guidelines" approved on 20 April 2006 by the Regions Conference, Emilio Stefanelli, Vice President of Farmindustria, and Giovanna Scroccaro, President of SIFO, who illustrated the point of view of the Pharmaceutical Industry and SIFO on the indicated topic.
The second part of the conference dealt with the theme "Proposals to improve the quality of Scientific Information on Medicines”, which was developed by Giampaolo Velo (University and Hospital of Verona. Smith-Kline Foundation working group), Salvatore Mannino (Head of Epidemiological Service - ASL Cremona) and Giuseppe Recchia (Vice President Medical and Regulatory - GSK).
In the third part of the Conference, a Panel discussion, which was attended by Claudio Cricelli (SIMG President), Angelo de Rita (AIISF President), Loredano Giorni (Head of Pharmaceutical Services of the Tuscany Region), Onofrio Palombella (Gov. & Reg. Affairs Director AstraZeneca) and Giovanna Scroccaro, President of SIFO. Moderator Claudio Jommi (Editor-in-Chief "Economics & Drug Policy" - Resp. Observ. Medicines CERGAS-SDA Univ. Bocconi). Participants answered the following questions:
1. What are the positive and negative aspects of the current regulation on medical-scientific information according to the different points of view of the players in the health system?
2. Without prejudice to the provisions of Law 326/03 regarding regional competences on medical-scientific information and the Guidelines of the Regional Regulations, is coordination of the regional initiatives between themselves and with AIFA and the pharmaceutical industry associations (through the State-Regions Conference) foreseeable, according to the provisions of article 119 of the Legislative Decree Scheme for the transposition of European directives?
3. Is it foreseeable that public information and business can work together to achieve a balance between managing demand (and rationalizing consumption) and adequate access to innovation, also given the "specialist" nature of various new drugs introduced on the market? If such a possibility exists, what are these spaces, what are the possible tools for collaboration and what is the role of the different actors?
As soon as possible we will publish the complete texts of all the interventions registered at the Conference.
